New Hope for Children: SciSparc’s patented CBD- Enhanced Solution for Autism Spectrum Disorder
TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder (ASD) symptoms in children.
SciSparc’s novel SCI-210 therapy is not only a medication based on CBD; it is also a unique combination of cannabidiol (CBD) and SciSparc’s proprietary Palmitoylethanolamide, aimed to ease the symptoms of ASD.
How will it work?
Over a period of 20 weeks, the trial will enroll 60 participants between the ages of 5-18 years old to scientifically measure how SCI-210 compares to standard CBD treatment in managing ASD symptoms. The trial is structured as a randomized, double-blind, placebo-controlled trial, which is the gold standard for clinical research.
Oz Adler, SciSparc’s Chief Executive Officer, stated, “Our pioneering treatment aims to reduce and alleviate the symptoms of autism along with reducing the side effects that are common when taking cannabis-based treatments, such as CBD. Partnering with the Soroka Medical Center and the National Autism Research Center, we are exploring new territory in ASD treatment. We are driven by science and the goal of improving life quality for children with ASD and their families.”
The spectrum of ASD is as diverse as the individuals it affects, challenging social interaction and communication. SciSparc’s bold initiative aims to offer a brighter, more connected future for those on the autism spectrum.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses: the goals and objectives of the SCI-210 clinical trial and the Company’s optimism that SCI-210 could be a pioneering ASD treatment. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
